SPECT/CT with ^{99m}Tc-MAA in Radioembolization with ^{90}Y Microspheres in Patients with Hepatocellular Cancer

Monia E. Hamami[1], Thorsten D. Poeppel[1], Stephan Müller[1], Till Heusner[2], Andreas Bockisch[1], Philipp Hilgard[3], and Gerald Antoch[2]

[1]Department of Nuclear Medicine, University Hospital Essen, University at Duisburg-Essen, Essen, Germany; [2]Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University at Duisburg-Essen, Essen, Germany; and [3]Department of Gastroenterology and Hepatology, University Hospital Essen, University at Duisburg-Essen, Essen, Germany

Radioembolization with ^{90}Y microspheres is a novel treatment for hepatic tumors. Generally, hepatic arteriography and ^{99m}Tc-macroaggregated albumin (MAA) scanning are performed before selective internal radiation therapy to detect extrahepatic shunting to the lung or the gastrointestinal tract. Whereas previous studies have used only planar or SPECT scans, the present study used ^{99m}Tc-MAA SPECT/CT scintigraphy (SPECT with integrated low-dose CT) to evaluate whether SPECT/CT and additional diagnostic contrast-enhanced CT before radioembolization with ^{90}Y microspheres are superior to SPECT or planar imaging alone for detection of gastrointestinal shunting. **Methods:** In a prospective study, we enrolled 58 patients (mean age, 66 y; SD, 12 y; 10 women and 48 men) with hepatocellular carcinoma who underwent hepatic arteriography and scintigraphy with ^{99m}Tc-MAA using planar imaging, SPECT, and SPECT with integrated low-dose CT of the upper abdomen (acquired with a hybrid SPECT/CT camera). The ability of the different imaging modalities to detect extrahepatic MAA shunting was compared. Patient follow-up of a mean of 180 d served as the standard of reference. **Results**: Gastrointestinal shunting was revealed by planar imaging in 4, by SPECT in 9, and by SPECT/CT in 16 of the 68 examinations. For planar imaging, the sensitivity for detection of gastrointestinal shunting was 25%, the specificity 87%, and the accuracy 72%. For SPECT without CT, the sensitivity was 56%, the specificity 87%, and the accuracy 79%. SPECT with CT fusion had a sensitivity of 100%, a specificity of 94%, and an accuracy of 96%. In 3 patients, MAA deposits in the portal vein could accurately be attributed to tumor thrombus only with additional information from contrast-enhanced CT. The follow-up did not show any gastrointestinal complications. **Conclusion:** SPECT with integrated low-dose CT using ^{99m}Tc-MAA is beneficial in radioembolization with ^{90}Y microspheres because it increases the sensitivity and specificity of ^{99m}Tc-MAA SPECT when detecting extrahepatic arterial shunting. The overall low risk of gastrointestinal complications in radioembolization may therefore be further reduced by SPECT/CT.

Radioembolization with ^{90}Y microspheres via hepatic arterial administration is emerging as a promising treatment for patients with primary and metastatic liver cancer (1–4). ^{90}Y microspheres are currently approved in the United States for the treatment of hepatocellular carcinoma (TheraSphere; MDS Nordion) and colorectal cancer (SIR-Spheres; Sirtex Medical). ^{90}Y microspheres are injected into the arterial supply of the liver, where they preferentially flow into hypervascularized tumor areas, resulting in a significantly higher irradiation of tumor tissue than of normal liver parenchyma (5). With improvements in technology permitting smaller vessels to be catheterized and refinements in imaging techniques, the safety and efficacy of ^{90}Y microsphere delivery has improved significantly (6–10).

Liver-directed therapy with ^{90}Y provides several advantages over traditional treatment methods because of its low toxicity profile (6,8). Although postembolization syndrome may occur in as many as 50% of patients after radioembolization with ^{90}Y microspheres, the severity is less than after transarterial chemoembolization (7–9,11). Rare but severe complications that may occur after administration of ^{90}Y include nontarget irradiation leading to gastrointestinal ulceration, pancreatitis, cholecystitis, or radiation pneumonitis (8,12–15). Because of these potential risks, careful patient selection is of the utmost importance (7,16,17). Aggressive prophylactic embolization during hepatic arteriography is recommended because ^{90}Y-induced ulcers may be refractory to medical therapy.

Generally, hepatic arteriography and ^{99m}Tc-macroaggregated albumin (MAA) scanning are performed before radioembolization with ^{90}Y microspheres to detect extra-

hepatic shunting to the lung or the gastrointestinal tract (16). Whereas previous studies have used only planar imaging or SPECT of the upper abdomen to assess MAA distribution, the present study used ^{99m}Tc-MAA SPECT/CT scintigraphy (SPECT with integrated low-dose CT). SPECT/CT, a dual-modality imaging system that provides functional (SPECT) and anatomic (CT) images in the same scanning session, is now widely used in many fields of cancer imaging, in dosimetry for radionuclide therapy (18–20), and in the monitoring of anticancer drug distribution (21).

This study evaluated whether SPECT/CT and additional diagnostic contrast-enhanced CT before selective internal radiation therapy may be superior to SPECT or planar imaging alone when assessing treatment with ^{90}Y microspheres in patients for gastrointestinal shunts before therapy.

MATERIALS AND METHODS

Patients

We enrolled 58 consecutive patients with unresectable HCC who underwent radioembolization with TheraSphere. The mean age was 66 y (range, 38–89 y). There were 10 women (17%) and 48 men (83%). Two of the 58 patients underwent separate MAA scans of the right and left liver lobes on different days. In 8 patients, MAA scans were repeated because of gastrointestinal shunting. Thus, 68 MAA scans were performed. Informed written consent was obtained from all patients before radioembolization with ^{90}Y microspheres. All patients underwent ^{99m}Tc-MAA planar imaging, SPECT, and SPECT/CT of the liver.

MAA Scanning

Depending on the anatomy of the patient, 150 MBq of ^{99m}Tc-MAA were injected with a microcatheter either into the proper hepatic artery or the common hepatic artery after coil embolization of all visible nonhepatic arterial flow. If injection into the common or proper hepatic artery was not possible, the left and right hepatic arteries were injected separately. In variant anatomies, accessory or replaced vessels were injected separately. After MAA injection, the patient was transferred to the nuclear medicine department for imaging.

Image Acquisition

Anterior and posterior planar images of the whole body were obtained within 30 min after the MAA injection, using a dual-detector γ-camera with a mounted 2-row CT scanner (Symbia T; Siemens Healthcare). SPECT/CT images of the upper abdomen were acquired immediately after the delayed planar images. Acquisition parameters for SPECT were a 128×128 matrix with 128 frames (25 s/frame). The scan parameters for CT were 130 kV, 17 mAs, 5-mm slices, and image reconstruction with a medium smooth kernel. SPECT images were corrected for attenuation and scatter. The reconstructed data were visualized in sagittal, coronal, and axial slices. Fusion images were generated from the coregistered SPECT and low-dose CT images using the Esoft 2007 application package (Siemens Healthcare).

Image Interpretation

All images were masked as to patient identity. The images were reviewed for extrahepatic MAA deposition on a Syngo workstation (VD20K; Siemens Healthcare) by an experienced nuclear medicine physician and a radiologist, who achieved consensus. Images were read in the following order with an interval of 4 wk between reading sessions: planar images, SPECT (non–attenuation-corrected), SPECT/CT, and then SPECT/CT in combination with diagnostic contrast-enhanced CT.

Reference Standard

A combination of clinical and radiologic follow-up served as the standard of reference for extrahepatic gastrointestinal shunting. This follow-up included physical examination and laboratory tests on days 2, 7, 14, 21, 28, 90, and 180 after the intervention. Abdominal contrast-enhanced ultrasound, CT, and MRI were performed on days 30, 90, and 180 postinterventionally.

Data Analysis

On the basis of the standard of reference, potential gastrointestinal shunts detected on planar imaging, SPECT, and SPECT/CT were rated as true-positive, true-negative, false-positive, or false-negative. Sensitivities, specificities, and accuracies were calculated for all imaging modalities.

RESULTS

Extrahepatic shunting was revealed by planar imaging in 4, SPECT in 9, and SPECT/CT in 16 of the 68 examinations (true-positives) (Table 1). The number of false-positive results was 7 for planar imaging (13%), 7 for SPECT (13%), and 3 for SPECT/CT (6%). The number of false-negative results was 12 for planar imaging (75%), 7 for SPECT (44%), and 0 for SPECT/CT (100%). On the basis of these findings, the sensitivity in detecting extrahepatic shunting with planar imaging was 25%, the specificity was 87%, and the accuracy was 72%. For SPECT, the sensitivity was 56%, the specificity was 87%, and the accuracy was 79%. SPECT/CT had a sensitivity of 100%, a specificity of 94%, and an accuracy of 96%. The different sites of MAA injection in patients with extrahepatic shunting on SPECT/CT are listed in Table 2.

Intensive nuclide deposition in the gallbladder was revealed in 4 patients by SPECT and in 6 by SPECT/CT. Two patients underwent elective cholecystectomy because

TABLE 1. Detection of Gastrointestinal Shunting with Planar Imaging, SPECT, and SPECT/CT

Imaging method	Accuracy	Sensitivity	Specificity
Planar	49/68 (72%)	4/16 (25%)	45/52 (87%)
SPECT	54/68 (79%)	9/16 (56%)	45/52 (87%)
SPECT/CT	65/68 (96%)	16/16 (100%)	49/52 (94%)

In 58 patients, 68 hepatic arteriographies and ^{99m}Tc-MAA scans with planar imaging, SPECT, and SPECT/CT were performed. Accuracies, sensitivities, and specificities were calculated to evaluate potential additive value of SPECT/CT compared with planar imaging or conventional SPECT. Difference between sensitivity of planar and SPECT/CT was statistically significant (χ^2 test, $P = 0.03$).

TABLE 2. Site of MAA Injection in Patients with Extrahepatic Shunting on SPECT/CT

MAA injection site	Extrahepatic shunting
Proper or common hepatic artery	6/16 (38%)
Right or left hepatic artery	10/16 (62%)

the intensity of MAA deposition in the gallbladder was greater than or equal to that in the tumor.

In 3 patients, MAA deposition in the liver hilum was misinterpreted as extrahepatic on SPECT/CT. Comparison of the SPECT/CT data of these 3 patients with previously acquired diagnostic contrast-enhanced CT showed that these MAA depositions were tumor uptake in portal vein tumor thrombi (Fig. 1). In 10 patients, extrahepatic MAA deposition was detected with SPECT/CT. This deposition was localized within the gastrointestinal tract in all patients. In 6 of these patients, the underlying vessel was found on repeated angiography and was coil embolized. In 2 others, the underlying vessel was detected but could not be embolized because of its small diameter. These patients were treated from a more distal catheter position. In the remaining 2 patients, no underlying artery was found on repeated angiography but MAA uptake persisted. These patients were not treated (Fig. 2). Thereby, nontarget seeding was successfully avoided.

No treated patient experienced gastrointestinal complications. None of the imaging modalities performed on days 30, 90, and 180 d after the treatment revealed signs of cholecystitis or pancreatitis. However, almost all patients experienced postembolization syndrome consisting of low-grade fever, loss of appetite, and fatigue for up to 6 wk after the treatment.

DISCUSSION

Our data show that SPECT with integrated low-dose CT before radioembolization with ^{90}Y microspheres is superior

FIGURE 1. SPECT/CT and triple-phase diagnostic CT in patient with tumor infiltration of portal vein. (A) Extrahepatic MAA deposition in liver hilum is seen on low-dose SPECT/CT. (B) Triple-phase diagnostic CT reveals tumor thrombus in right branch of portal vein extending into main branch of portal vein. Finding on contrast-enhanced CT corresponds to MAA uptake on SPECT/CT.

to SPECT or planar imaging alone in the detection of gastrointestinal MAA deposition. Additional diagnostic contrast-enhanced CT further increases specificity in patients with portal vein thrombosis by differentiating tumor-associated MAA deposition in the portal vein from that in extrahepatic locations.

We found approximately 40% more patients with gastrointestinal MAA accumulation using SPECT/CT than with SPECT alone (16 vs. 9 of 68 examinations). Planar scanning was able to detect gastrointestinal MAA deposition in only 4 patients. Although SPECT or planar scanning is widely used before radioembolization with ^{90}Y microspheres (9,16,17), data on their accuracy to detect gastrointestinal MAA deposition have only rarely been published. To date, the value of SPECT/CT before treatment with ^{90}Y microspheres has been investigated only in patients with colorectal cancer, and consistent with our data, Denecke et al. found more gastrointestinal MAA uptake using SPECT/CT than using SPECT (16).

In our study, the follow-up did not show any case of gastrointestinal adverse events. Previous investigations, however, have reported gastrointestinal complications after radioembolization. Jakobs et al. published a series of 39 patients treated with ^{90}Y microspheres and reported a patient with an actinic gastric ulcer and a patient with edematous pancreatitis, which was most likely the result of ectopic embolization via undetected vascular branches into these organ territories (2). Dancey et al. found gastrointestinal ulcers in 3 of 22 patients (3). Neither study involved SPECT/CT in the planning of radioembolization with ^{90}Y microspheres. Although gastrointestinal complications are rare and their incidence may decrease with an increasing learning curve, according to the cited studies it may be assumed that the use of SPECT/CT in planning radioembolization with ^{90}Y microspheres may contribute to the safety of this treatment modality. However, larger patient series are required to support this hypothesis.

The reference standard consisting of clinical and radiologic follow-up may be considered a limitation of the study. The most reliable reference standard for extrahepatic radionuclide deposition may have been endoscopy with biopsy of visually suggestive regions of the gastrointestinal wall. However, this approach would have been rather invasive and would not have included the mid and distal portions of the small intestine or any nongastrointestinal sites (e.g., the pancreas, the abdominal wall, lymph nodes). We, therefore, decided on a combination of clinical and radiologic follow-up as the standard of reference. Another limitation may be the fact that all patients with gastrointestinal MAA deposition were excluded from treatment with ^{90}Y microspheres in this analysis if no causative gastrointestinal vessel was identified. It is not clear whether these patients would really have been affected by gastrointestinal side effects if they had been treated. Therefore, a presumably safer algorithm avoiding

FIGURE 2. SPECT/CT and angiography in 76-y-old man with HCC in right liver lobe. During the first angiography examination, MAA was injected into proximal right hepatic artery. No vessel leading to gastrointestinal tract was detected. (A) Strong tracer uptake (arrow) on SPECT was misinterpreted as segment 4 MAA uptake. (B) SPECT/CT localized MAA deposition (arrow) to duodenum. (C) On repeated angiography, small gastrointestinal vessel (arrow) originating from proximal right hepatic artery was detected. Repeated MAA injection was performed distally from this small vessel, and no shunting was visible on the following SPECT/CT.

RGB

gastrointestinal side effects may also lead to exclusion of more patients from therapy, as other algorithms probably will.

We initially misinterpreted SPECT/CT scans in 3 patients with MAA accumulation in the liver hilum. Subsequent diagnostic contrast-enhanced CT was able to locate the tracer accumulation in the portal vein, indicating tumor invasion as a common finding in patients with advanced HCC (22). In these 3 patients, the exclusion of extrahepatic MAA deposition was important to enable radioembolization with ^{90}Y microspheres. In view of these cases, a SPECT/CT protocol including diagnostic CT data (full-dose CT with contrast agents) may be discussed.

Occasionally, radioembolization may lead to radiation-induced cholecystitis (7,12,23). Both SPECT and SPECT/CT revealed patients with MAA depositions in the gallbladder. Unfortunately, in 2 of these patients it was not possible to position the catheter distal to the cystic artery because otherwise some parts of the tumor tissue would not have been sufficiently irradiated. In our study, these patients underwent cholecystectomy. However, we do not know if radiation-induced cholecystitis would have developed in these patients had they not undergone cholecystectomy. The risk of radiation-induced cholecystitis, when microspheres are infused from a catheter proximal to the cystic artery, has been discussed controversially. Our current approach includes prophylactic cholecystectomy in those patients in whom MAA uptake in the gallbladder wall is above the level of the nontumorous liver parenchyma. Nevertheless, dosimetric models and animal experiments are required to estimate the dose–effect relationship with regard to cholecystitis.

CONCLUSION

SPECT with integrated low-dose CT using ^{99m}Tc-MAA is beneficial in radioembolization with ^{90}Y microspheres because it increases the sensitivity and specificity of ^{99m}Tc-MAA SPECT when detecting extrahepatic arterial shunting. The overall low risk of gastrointestinal complications in radioembolization may therefore be further reduced by SPECT/CT.

REFERENCES

1. Blanchard RJ, Morrow IM, Sutherland JB. Treatment of liver tumors with yttrium-90 microspheres alone. *Can Assoc Radiol J.* 1989;40:206–210.
2. Jakobs TF, Hoffmann RT, Poepperl G, et al. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using ^{90}yttrium resin-microspheres. *Eur Radiol.* 2007;17:1320–1330.
3. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic ^{90}Y-microspheres. *J Nucl Med.* 2000;41:1673–1681.
4. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. *Gastroenterology.* 2004; 127(5, suppl 1)S194–S205.
5. Breedis C, Young G. The blood supply of neoplasms in the liver. *Am J Pathol.* 1954;30:969–977.
6. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. *J Vasc Interv Radiol.* 2005;16:195–203.
7. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. *Radiographics.* 2005;25 (suppl 1):S41–S55.
8. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of ^{90}Y microspheres (TheraSphere): safety, tumor response, and survival. *J Vasc Interv Radiol.* 2005;16:1627–1639.
9. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3—comprehensive literature review and future direction. *J Vasc Interv Radiol.* 2006;17:1571–1593.
10. Szyszko T, Al-Nahhas A, Tait P, et al. Management and prevention of adverse effects related to treatment of liver tumours with ^{90}Y microspheres. *Nucl Med Commun.* 2007;28:21–24.
11. Carr BI. Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients. *Hepatogastroenterology.* 2002;49:79–86.
12. Jiao LR, Szyszko T, Al-Nahhas A, et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. *Eur J Surg Oncol.* 2007;33:597–602.
13. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. *J Vasc Interv Radiol.* 2005;16:205–213.
14. Yip D, Allen R, Ashton C, Jain S. Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer. *J Gastroenterol Hepatol.* 2004;19: 347–349.
15. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial ^{90}yttrium-microspheres for inoperable hepatic tumors. *Int J Radiat Oncol Biol Phys.* 1995;33:919–924.
16. Denecke T, Ruhl R, Hildebrandt B, et al. Planning transarterial radioembolization of colorectal liver metastases with yttrium 90 microspheres: evaluation of a

sequential diagnostic approach using radiologic and nuclear medicine imaging techniques. *Eur Radiol.* 2008;18:892–902.

17. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. *Int J Radiat Oncol Biol Phys.* 2007;68:13–23.

18. Krausz Y, Keidar Z, Kogan I, et al. SPECT/CT hybrid imaging with ^{111}In-pentetreotide in assessment of neuroendocrine tumours. *Clin Endocrinol (Oxf).* 2003;59:565–573.

19. Boucek JA, Turner JH. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in ^{131}I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. *Eur J Nucl Med Mol Imaging.* 2005;32:458–469.

20. Schillaci O, Simonetti G. Fusion imaging in nuclear medicine: applications of dual-modality systems in oncology. *Cancer Biother Radiopharm.* 2004;19: 1–10.

21. Ikeda O, Tamura Y, Nakasone Y, et al. Evaluation of extrahepatic perfusion of anticancer drugs in the right gastric arterial region on fused images using combined CT/SPECT: is extrahepatic perfusion predictive of gastric toxicity? *Cardiovasc Intervent Radiol.* 2007;30:392–397.

22. Connolly GC, Chen R, Hyrien O, et al. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. *Thromb Res.* 2008;122:299–306.

23. Carr BI. Hepatic arterial [90]yttrium glass microspheres (TheraSphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. *Liver Transpl.* 2004; 10(2, suppl 1)S107–S110.